BIOHAVEN PHARMAC.HLDG CO.

Biohaven grants SK Biopharmaceuticals exclusive worldwide rights to the Kv7 ion‑channel platform, including epilepsy candidate Opakalim (BHV‑7000). The agreement can total up to $795 million, of which $400 million is cash up front, but it results in the expected phase‑2/3 RISE3 study being removed from Biohaven’s pipeline. Investors reacted with a "sell the news" move, amplified by an earlier downgrade from Bank of America and a revaluation of the remaining immunology and oncology programs. A separate $4 million trade‑secret judgment in Biohaven’s favor provided only limited support. » More on de.investing.com

SK Biopharmaceuticals acquires worldwide rights to Opakalim, a series of Kv7 activators, and Biohaven’s Kv7 research platform for up to $795 million, including an upfront payment of $400 million (350 million at closing, 50 million one year later). The announcement drove the share price up 10.5%. Analysts confirm a positive outlook: Heungkuk Securities reaffirmed its buy recommendation with a price target of 140,000 KRW, citing strong revenue and prescription growth in the epilepsy business. » More on de.investing.com

A U.S. district court in Delaware ruled for Biohaven and Yale, affirming a jury verdict totaling $4 million for misappropriation of trade secrets and breach of contract. Judge Jennifer L. Hall based the decision on findings that RA Capital and Avilar misused confidential information about Yale’s MODA platform and violated a confidentiality agreement. The court awarded Yale $2 million for the breach of contract; $1 million each went to Yale and Biohaven for misappropriation of trade secrets. Biohaven had licensed Yale’s MODA platform; the parties may still file additional motions with the court. » More on de.investing.com